Nexien Biopharma Financials
Financial Health Signals
Nexien Biopharma passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Nexien Biopharma generates $0.27 in operating cash flow (-$64K OCF vs -$239K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Nexien Biopharma (NXEN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Nexien Biopharma reported -$239K in net income in fiscal year 2024. This represents an increase of 33.9% from the prior year.
Nexien Biopharma earned $0.00 per diluted share (EPS) in fiscal year 2024. This represents an increase of 100.0% from the prior year.
Nexien Biopharma held $4K in cash against $0 in long-term debt as of fiscal year 2024.
Nexien Biopharma had 70M shares outstanding in fiscal year 2024. This represents an increase of 10.1% from the prior year.
Nexien Biopharma invested $0 in research and development in fiscal year 2024.
NXEN Income Statement
| Metric | Q3'25 | Q3'24 | Q3'23 | Q2'23 | Q3'22 | Q2'22 | Q3'21 | Q2'21 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $0 | $0 | $0 | N/A | $0 | N/A | N/A | N/A |
| SG&A Expenses | $5K-38.1% | $8K+2.5% | $8K | N/A | $67K | N/A | $202K | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | $10.4M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$30K+23.8% | -$39K-61.0% | -$25K | N/A | -$94K | N/A | -$220K | N/A |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | N/A | $0.00 | N/A | N/A | N/A |
NXEN Balance Sheet
| Metric | Q3'25 | Q3'24 | Q3'23 | Q2'23 | Q3'22 | Q2'22 | Q3'21 | Q2'21 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $8K+534.4% | $1K-50.1% | $3K-93.9% | $43K-44.0% | $77K-38.2% | $125K+4132.4% | $3K-88.5% | $26K |
| Current Assets | $8K+534.4% | $1K-50.1% | $3K-93.9% | $43K-44.0% | $77K-38.2% | $125K+4132.4% | $3K-88.5% | $26K |
| Cash & Equivalents | $8K+534.4% | $1K-50.1% | $3K-92.5% | $35K-49.1% | $69K-41.0% | $117K+3873.4% | $3K-83.7% | $18K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $459K+8.2% | $424K+33.8% | $317K+7.3% | $295K+5.7% | $279K+15.4% | $242K+270.4% | $65K+66.3% | $39K |
| Current Liabilities | $459K+8.2% | $424K+33.8% | $317K+7.3% | $295K+5.7% | $279K+15.4% | $242K+270.4% | $65K+66.3% | $39K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$451K-6.6% | -$423K-34.5% | -$314K-24.7% | -$252K-24.6% | -$202K-72.0% | -$118K-88.4% | -$62K-353.2% | -$14K |
| Retained Earnings | -$11.6M-0.3% | -$11.6M-1.9% | -$11.4M-0.9% | -$11.3M-1.6% | -$11.1M-1.7% | -$10.9M-2.7% | -$10.6M-3.3% | -$10.3M |
NXEN Cash Flow Statement
| Metric | Q3'25 | Q3'24 | Q3'23 | Q2'23 | Q3'22 | Q2'22 | Q3'21 | Q2'21 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$13K+54.5% | -$29K-85.5% | -$15K+19.0% | -$19K+40.7% | -$32K-37.9% | -$23K-48.0% | -$16K+51.6% | -$33K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $20K-20.0% | $25K | N/A | N/A | $159K | $0 | $0-100.0% | $20K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
NXEN Financial Ratios
| Metric | Q3'25 | Q3'24 | Q3'23 | Q2'23 | Q3'22 | Q2'22 | Q3'21 | Q2'21 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | 1014.7% | N/A |
| Return on Assets | -363.2%+2659.2pp | -3022.4%-2086.2pp | -936.2% | N/A | -121.6% | N/A | -7484.5% | N/A |
| Current Ratio | 0.02+0.0 | 0.000.0 | 0.01-0.1 | 0.15-0.1 | 0.28-0.2 | 0.51+0.5 | 0.04-0.6 | 0.65 |
| Debt-to-Equity | -1.02-0.0 | -1.000.0 | -1.01+0.2 | -1.17+0.2 | -1.38+0.7 | -2.06-1.0 | -1.05+1.8 | -2.85 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$361K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.01), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
Is Nexien Biopharma profitable?
No, Nexien Biopharma (NXEN) reported a net income of -$239K in fiscal year 2024.
What is Nexien Biopharma's earnings per share (EPS)?
Nexien Biopharma (NXEN) reported diluted earnings per share of $0.00 for fiscal year 2024. This represents a 100.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Nexien Biopharma's operating cash flow?
Nexien Biopharma (NXEN) generated -$64K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Nexien Biopharma's total assets?
Nexien Biopharma (NXEN) had $4K in total assets as of fiscal year 2024, including both current and long-term assets.
How many shares does Nexien Biopharma have outstanding?
Nexien Biopharma (NXEN) had 70M shares outstanding as of fiscal year 2024.
What is Nexien Biopharma's current ratio?
Nexien Biopharma (NXEN) had a current ratio of 0.01 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Nexien Biopharma's debt-to-equity ratio?
Nexien Biopharma (NXEN) had a debt-to-equity ratio of -1.01 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nexien Biopharma's return on assets (ROA)?
Nexien Biopharma (NXEN) had a return on assets of -5716.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Nexien Biopharma's cash runway?
Based on fiscal year 2024 data, Nexien Biopharma (NXEN) had $4K in cash against an annual operating cash burn of $64K. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Nexien Biopharma's debt-to-equity ratio negative or unusual?
Nexien Biopharma (NXEN) has negative shareholder equity of -$361K as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Nexien Biopharma's Piotroski F-Score?
Nexien Biopharma (NXEN) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nexien Biopharma's earnings high quality?
Nexien Biopharma (NXEN) has an earnings quality ratio of 0.27x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.